| 产品名称 | Peptides EP11243_1 | HIV env 816-825 (HLA-A*02:01) |
|---|---|
| 目录号 | EP11243_1 |
| 别名 | HIV env 816-825 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP11243_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP11243_1 | HIV env 816-825 (HLA-A*02:01)
品名：HIV env 816-825 (HLA-A*02:01)
货号：EP11243_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape. SLLNATAIAV had a significantly positive association with HLA A*02; it was recognized by 23/134 A*02-positive subjects and 9/190 A*02-negative subjects.
| Protein | Envelope glycoprotein gp160 |
| Species | HIV |
| Application | Flow Cytometry, Immunohistochemistry |
| Indication | Infectious disease |
